SMS Lifesciences India (SMS) has agreed to acquire Mahi Drugs Private Limited.

Based in India, the acquirer company is involved in product manufacturing, while the target company, also based in India, is a manufacturer of active pharmaceutical ingredients (APIs).

Merck & Co has signed an agreement to acquire Viralytics through its subsidiary.

Viralytics will become a subsidiary of Merck, upon completion of the transaction in Q2 2018.

Merck will obtain full rights to Viralytics’s investigational oncolytic immunotherapy CAVATAK (CVA21), as part of the transaction.

Based in the US, Merck is a biopharmaceutical company, while Viralytics is an Australian oncolytic immunotherapies developer.

“Merck & Co has signed an agreement to acquire Viralytics through its subsidiary.”

Merck has appointed Credit Suisse Securities (USA) as financial advisor, and Baker & McKenzie as legal advisor, while Viralytics selected Lazard as financial advisor and McCullough Robertson as legal advisor for the transaction.

Pharmaceutical company Teijin has agreed to purchase a controlling interest in medical device provider MedTech Heart from venture capital firm Seeds Rocket.

Teijin also will acquire MedTecHeart, a subsidiary of the MedTech Heart, as part of the transaction.

The two companies will be incorporated into a new entity named Teijin MedTecHeart.

Both the acquirer and target companies are based in Japan.